Cypress Asset Management Inc. TX Buys New Shares in Novo Nordisk A/S (NYSE:NVO)

Cypress Asset Management Inc. TX bought a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 18,072 shares of the company's stock, valued at approximately $1,620,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Center for Financial Planning Inc. increased its stake in Novo Nordisk A/S by 72.4% in the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after acquiring an additional 123 shares during the period. Strategic Investment Solutions Inc. IL increased its stake in Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the period. Transce3nd LLC bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $33,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $39,000. Finally, Fourth Dimension Wealth LLC bought a new stake in Novo Nordisk A/S during the fourth quarter worth about $41,000. Institutional investors own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the topic of several research analyst reports. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Stifel Nicolaus cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Finally, Wall Street Zen raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Trading Up 4.5%

NYSE NVO traded up $3.04 during trading hours on Tuesday, hitting $70.39. The company's stock had a trading volume of 9,168,584 shares, compared to its average volume of 6,711,485. The stock has a fifty day moving average of $66.07 and a 200 day moving average of $82.47. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The firm has a market capitalization of $315.88 billion, a P/E ratio of 21.40, a PEG ratio of 0.90 and a beta of 0.65. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The business had revenue of $11.87 billion for the quarter. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.